FDA批准匹米替尼用于有症状的腱鞘巨细胞瘤
正文 · 中文译文
FDA批准匹米替尼用于有症状的腱鞘巨细胞瘤 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2026年11月10日,美国食品药品监督管理局(FDA)批准匹米替尼(Pimjetmi,EMD Serono,Inc.),一种激酶抑制剂,用于患有有症状的腱鞘巨细胞瘤(TGCT)且手术切除可能导致功能受限恶化或严重病残的成人患者。 Pimjetmi的完整处方信息将发布在Drugs@FDA上。 疗效与安全性 疗效在MANEUVER(NCT05804045)中进行了评估,这是一项双盲、随机(2:1)、安慰剂对照的国际试验,纳入手术切除可能导致功能障碍或严重并发症的TGCT患者。符合条件的患者须确诊为有症状的TGCT,具有可测量病灶,且至少一个病灶最小尺寸为2 cm。患者被随机分配至匹米替尼50 mg或安慰剂每日一次。随机化按地理区域(中国与非中国)进行分层。 主要疗效结局指标为第25周时经盲态独立中心审查(BICR)依据RECIST v1.1评估的总体缓解率(ORR)。pimicotinib组ORR为56%(95% CI:42,68),安慰剂组为3.2%(95% CI:0.1,17)。pimicotinib组中位缓解持续时间(DOR)未达到;32例缓解者(91%)DOR≥6个月,27例(77%)DOR≥12个月。此外,第25周时,pimicotinib组在预设的患者报告和功能终点方面相较安慰剂组观察到统计学显著改善。接受pimicotinib治疗的患者在测角评估测量的受累关节主动活动范围方面获得改善,简明疼痛评估量表(BPI)最严重疼痛数字评定量表(NRS)测量的最严重疼痛减轻,患者报告结局测量信息系统(PROMIS)躯体功能T评分测量的躯体功能改善。 最常见(>20%)的不良反应为瘙痒、皮疹、面部水肿、眶周水肿、疲乏、恶心、头痛和外周水肿。最常见(>30%)的实验室异常为肌酸磷酸激酶升高、乳酸脱氢酶升高、天冬氨酸氨基转移酶升高、脂肪酶升高、胆固醇升高、淀粉酶升高和丙氨酸氨基转移酶升高。 处方信息包括肝毒性、胚胎-胎儿毒性以及血清肌酐升高但不影响肾功能的警告和注意事项。 推荐剂量 推荐pimicotinib剂量为50 mg口服,每日一次,可与食物同服或空腹服用。 本审评在Project Orbis框架下开展,该项目为FDA肿瘤卓越中心的一项倡议。Project Orbis为国际合作伙伴之间肿瘤药物的同步提交和审评提供了框架。本次审评中,FDA与澳大利亚治疗用品管理局(TGA)、加拿大卫生部(HC)、以色列卫生部(ImoH)、瑞士瑞士药品监督管理局(SMC)以及英国药品和保健产品监管局(MHRA)合作。欧洲药品管理局(EMA)为本次审评的正式观察员。相关申请可能正在其他监管机构进行提交程序或仍处于审评中。 本次审评使用了Assessment Aid,这是申请人自愿提交以协助FDA评估的文件。 Pimicotinib获得了快速通道和突破性疗法认定。FDA加速程序的描述见《行业指南:严重疾病的加速程序——药物和生物制品》。 医疗保健专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需获得研究性肿瘤产品单患者IND方面的协助,医疗保健专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 内容更新日期: 11/10/2026 监管产品类别 药物 肿瘤学
正文 · 英文原文
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. Full prescribing information for Pimjetmi will be posted on Drugs@FDA. Efficacy and Safety Efficacy was evaluated in MANEUVER (NCT05804045), a double-blind, randomized (2:1), placebo-controlled, international trial in patients with TGCT for whom surgical resection may cause dysfunction or serious complications. Eligible patients had a confirmed diagnosis of symptomatic TGCT with measurable disease with at least one lesion having a minimum size of 2 cm. Patients were randomized to pimicotinib 50 mg or placebo once daily. Randomization was stratified by geographic region (China versus non-China). The major efficacy outcome measure was overall response rate (ORR), as assessed by blinded independent central review (BICR) per RECIST v1.1 at Week 25. ORR was 56% (95% CI: 42, 68) in the pimicotinib arm and 3.2% (95% CI: 0.1, 17) in the placebo arm. Median duration of response (DOR) was not reached in the pimicotinib arm; 32 responders (91%) had a DOR ≥6 months and 27 (77%) had a DOR ≥12 months. In addition, statistically significant improvements were observed in the pimicotinib arm compared to the placebo arm at Week 25 across prespecified patient-reported and functional endpoints. Patients treated with pimicotinib experienced gains in active range of motion of the affected joint as measured by goniometry assessments, a reduction in worst pain as measured by the Brief Pain Inventory (BPI) Worst Pain Numeric Rating Scale (NRS), and improved physical functioning as measured by the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function T-score. The most common (>20%) adverse reactions were pruritus, rash, face edema, periorbital edema, fatigue, nausea, headache, and peripheral edema. The most common (>30%) lab abnormalities were creatine phosphokinase increased, lactate dehydrogenase increased, aspartate aminotransferase increased, lipase increased, cholesterol increased, amylase increased, and alanine aminotransferase increased. The prescribing information includes warnings and precautions for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without affecting renal function. Recommended Dosage The recommended pimicotinib dosage is 50 mg orally once daily with or without food. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada (HC), Israel’s Ministry of Health (ImoH), Switzerland’s Swissmedic (SMC), and United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The European Medicines Agency (EMA) was an official observer of this review. The applications may be undergoing the submission process or still be under review at the other regulatory agencies. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. Pimicotinib received fast track and breakthrough therapy designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Content current as of: 11/10/2026 Regulated Product(s) Drugs Oncology